# Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

> **NCT00278421** · PHASE3 · COMPLETED · sponsor: **German High-Grade Non-Hodgkin's Lymphoma Study Group** · enrollment: 592 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00278421
- **Lead sponsor:** German High-Grade Non-Hodgkin's Lymphoma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 592 (ACTUAL)
- **Last updated:** 2021-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278421, "Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00278421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*